Literature DB >> 22241019

Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.

Y J Choi1, H T Lim, S J Lee, S Y Lee, J S Yoon.   

Abstract

AIM: To investigate the clinical significance of Grave's ophthalmopathy-specific quality of life (GO-QOL) in Korean patients.
METHODS: A cross-sectional study was conducted at the Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea, on 98 consecutive Grave's ophthalmopathy (GO) patients. The GO-QOL survey provided by Terwee and colleagues and suggested by the European group on Graves' orbitopathy (EUGOGO) was translated into Korean language and distributed to study participants. Clinical severity was judged by scores of the modified NOSPECS classification, and inflammatory activity was measured by a seven-point scale of clinical activity score (CAS).
RESULTS: The mean GO-QOL scores were 73.7 (standard deviation (SD), 26) for visual functioning, 61.9 (SD 26) for appearance, and 67.8 for total quality of life (QOL; SD 22). The worse QOL scores for each part were significantly associated with the higher modified NOSPECS score and CAS after adjusting for confounders such as age and sex (P<0.05, respectively). In particular, decreased QOL scores for visual function were significantly correlated with a higher grade of extraocular muscle involvement (P<0.05). Lower QOL scores for appearance were associated with more severe soft-tissue involvement and proptosis (P<0.05, respectively).
CONCLUSIONS: GO-QOL suggested by EUGOGO showed correlation with objective clinical parameters. GO-QOL can be a simple and effective tool in the evaluation of the clinical and psychological illness of GO patients.

Entities:  

Mesh:

Year:  2012        PMID: 22241019      PMCID: PMC3325578          DOI: 10.1038/eye.2011.359

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  14 in total

1.  Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments.

Authors:  C B Terwee; F W Dekker; M P Mourits; M N Gerding; L Baldeschi; R Kalmann; M F Prummel; W M Wiersinga
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

Review 2.  Thyroid-associated eye disease: pathophysiology.

Authors:  A P Weetman
Journal:  Lancet       Date:  1991-07-06       Impact factor: 79.321

3.  Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison J Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten P Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Thyroid       Date:  2008-03       Impact factor: 6.568

4.  Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease.

Authors:  Anja K Eckstein; Marco Plicht; Hildegard Lax; Markus Neuhäuser; Klaus Mann; Sebastian Lederbogen; Christian Heckmann; Joachim Esser; Nils G Morgenthaler
Journal:  J Clin Endocrinol Metab       Date:  2006-07-11       Impact factor: 5.958

Review 5.  Graves' ophthalmopathy: current concepts regarding pathogenesis and management.

Authors:  H B Burch; L Wartofsky
Journal:  Endocr Rev       Date:  1993-12       Impact factor: 19.871

6.  Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin.

Authors:  M Tellez; J Cooper; C Edmonds
Journal:  Clin Endocrinol (Oxf)       Date:  1992-03       Impact factor: 3.478

7.  Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.

Authors:  Elizabeth A Bradley; Jeff A Sloan; Paul J Novotny; James A Garrity; John J Woog; Sheila K West
Journal:  Ophthalmology       Date:  2006-06-12       Impact factor: 12.079

8.  Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.

Authors:  M N Gerding; C B Terwee; F W Dekker; L Koornneef; M F Prummel; W M Wiersinga
Journal:  Thyroid       Date:  1997-12       Impact factor: 6.568

9.  Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL.

Authors:  C B Terwee; M N Gerding; F W Dekker; M F Prummel; W M Wiersinga
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

10.  Assessing quality of life in Australian patients with Graves' ophthalmopathy.

Authors:  J J Park; T J Sullivan; R H Mortimer; M Wagenaar; D A Perry-Keene
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

View more
  10 in total

1.  Which factors are associated with quality of life in patients with Graves' orbitopathy presenting for orbital decompression surgery?

Authors:  S Wickwar; H B McBain; D G Ezra; S P Hirani; G E Rose; S P Newman
Journal:  Eye (Lond)       Date:  2015-05-22       Impact factor: 3.775

2.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

3.  Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy.

Authors:  Luigi Bartalena; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2020-09-21

4.  Long-term effect of triamcinolone acetonide in the treatment of upper lid retraction with thyroid associated ophthalmopathy.

Authors:  Dong-Dong Xu; Yu Chen; Hai-Yan Xu; Hui Li; Zhu-Hua Zhang; Yu-Hua Liu
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

5.  Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.

Authors:  Sung Jun Lee; Tyler Hyung Taek Rim; Sun Young Jang; Chan Yun Kim; Dong Yeob Shin; Eun Jig Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-12       Impact factor: 3.117

6.  Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.

Authors:  Elena Hoppe; Alan Chun Hong Lee; David Hoppe; George J Kahaly
Journal:  Eur Thyroid J       Date:  2020-07-02

7.  Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.

Authors:  Peng Zeng; Shu-Xian Fan; Zi-Jing Li; Yuan-Yu Peng; Yu-Xin Hu; Ming-Tong Xu; Mei Wang
Journal:  J Ophthalmol       Date:  2019-03-18       Impact factor: 1.909

8.  Assessing the quality of life in Indian Graves' orbitopathy patients and validation of Hindi version of GO-QOL questionnaire.

Authors:  Kishan Delampady; Sagili Vijaya Bhaskar Reddy; Subhash B Yadav
Journal:  Indian J Ophthalmol       Date:  2020-08       Impact factor: 1.848

9.  Psychometric properties of the thyroid-specific quality of life questionnaire ThyPRO in Singaporean patients with Graves' disease.

Authors:  Huiling Liew; Torquil Watt; Luo Nan; Alvin W K Tan; Yiong Huak Chan; Daniel Ek Kwang Chew; Rinkoo Dalan
Journal:  J Patient Rep Outcomes       Date:  2021-07-08

10.  Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.

Authors:  Mingkwan Lumyongsatien; Benjama Keeratidamkerngsakul; Kanokrat Pornpanich; Sumalee Vangveeravong; Preamjit Saonanon; Damrong Wiwatwongwana; Pornchai Mahaisavariya; Orapan Aryasit; Krit Pongpirul
Journal:  J Patient Rep Outcomes       Date:  2019-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.